A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Launched by SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SHR-A2102 in combination with other cancer therapies for patients with advanced solid tumors, which are types of cancer that form in tissues such as organs. The goal of the study is to find out how safe the treatment is, how well it works, and the best dosage for patients. The trial is currently looking for participants aged 18 to 70 who have at least one measurable tumor and are in relatively good health, meaning they can carry out everyday activities without too much difficulty.

If you or a loved one are considering joining this trial, you should know that participants will receive close monitoring throughout the study to ensure their safety. They will need to be able to provide informed consent, meaning they understand the trial and agree to participate. It's important to note that certain conditions, like untreated brain metastases or severe heart problems, may prevent someone from joining. Overall, this trial aims to explore new treatment options for patients with advanced solid tumors and contribute to future cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The age of signing the informed consent is 18 -70 years, regardless of gender.
• • 2. At least one measurable lesion according to RECIST v1.1 criteria.
• • 3. The ECOG score is 0 or 1.
• • 4. Expected survival ≥12 weeks.
• • 5. Good level of organ function.
• • 6. Have the ability to give informed consent and to comply with the treatment plan.
• • 7. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.
• Exclusion Criteria:
• • 1. Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases.
• • 2. Spinal cord compression not cured by surgery and/or radiotherapy.
• • 3. Subjects with uncontrolled tumor-related pain.
• • 4. Received antitumor therapy within 4 weeks before the start of the study.
• • 5. Subjects with severe cardiovascular and cerebrovascular disease.
• • 6. History of immunodeficiency, including a positive HIV test.